Evidence map›Paper›PMID 28526278›Full record

ReviewThe journal of allergy and clinical immunology. In practice

Biotherapeutics in Chronic Rhinosinusitis with and without Nasal Polyps.

Claus Bachert, Philippe Gevaert, Peter Hellings

Abstract readReview
PubMed Publisher
In one paragraph

Review in The journal of allergy and clinical immunology. In practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
10.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 104 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Trial
  4. Review
  5. Article
  6. Review
  7. Observational
  8. Review
  9. Vitamin D and Interleukins in Chronic Rhinosinusitis with Polyposis.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2022
    Article
  10. Article
  11. Anti-phospholipid antibodies are elevated and functionally active in chronic rhinosinusitis with nasal polyps.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2022
    Article
  12. Article
  13. Review
  14. Allergo Journal : interdisziplinare Zeitschrift fur Allergologie und Umweltmedizin : Organ der Deutschen Gesellschaft fur Allergie- und Immunitatsforschung · 2022
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Claus BachertUpper Airways Research Laboratory, Ghent University, Ghent, Belgium; Division of ENT Diseases, CLINTEC, Karolinska Institute, Stockholm, Sweden. Electronic address: claus.bachert@ugent.be.
Philippe GevaertUpper Airways Research Laboratory, Ghent University, Ghent, Belgium.
Peter HellingsDepartment of Otorhinolaryngology, HNS, UZ Leuven, Leuven, Belgium.
Ghent University · BEUniversitair Ziekenhuis Leuven · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In western countries, 85% of chronic rhinosinusitis with nasal polyp disease reveals a type 2 inflammatory pattern with expression of IL-4, -5, and -13 as well as increased concentrations of IgE, whereas chronic rhinosinusitis without nasal polyps merely expresses these biomarkers. The degree of type 2 inflammation furthermore is associated with disease severity, asthma comorbidity, and recurrence of disease after surgery. Therefore, these biomarkers also form the targets for innovative therapeutic approaches such as monoclonal antibodies directed against IgE, IL-5, and IL-4 receptor alpha, blocking the activity of IL-4 and -13. Having demonstrated efficacy in severe asthma, the antibodies have been tested in proof-of-concept studies in patients with nasal polyposis with or without asthma, and have demonstrated their potential to reduce nasal and sinus nasal polyp burden monitored by nasal endoscopy and computed tomography scanning, and to improve typical symptoms. No biomarkers have been identified to select subjects for therapy, to predict response to a specific drug, or to monitor treatment success, which is best documented by nasal polyp score and symptoms. Phase 3 studies are currently in preparation or running, which aim to demonstrate efficacy in larger patient populations and to achieve registration for the indication nasal polyps.

Indexed as

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedBiological TherapyChronic DiseaseClinical Trials as TopicCytokinesHumansImmunotherapyNasal PolypsOmalizumabQuality of LifeRhinitisSinusitisTh2 CellsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedCytokinesdupilumabmepolizumabOmalizumabBiologicsBiomarkersChronic rhinosinusitisDupilumabEndotypeMepolizumabNasal polypsOmalizumabType 2 inflammation

Identifiers

PMID28526278
OpenAlexW2616060585

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.